CAS: 6092-18-8; N-((4-Amino-2-Methylpyrimidin-5-yl)Methyl)-N-(1-(2-Oxo-1,3-Oxathian-4-Ylidene)Ethyl)Formamide
- 英文名称N-((4-Amino-2-Methylpyrimidin-5-yl)Methyl)-N-(1-(2-Oxo-1,3-Oxathian-4-Ylidene)Ethyl)Formamide
- 中文名称噻内脂硫胺
- IUPAC名称N-((4-amino-2-methylpyrimidin-5-yl)methyl)-N-(1-(2-oxo-1,3-oxathian-4-ylidene)ethyl)formamide
- 其它别名Cycotiamine; Cycotiamin; N-[(4-Amino-2-Methyl-5-Pyrimidinyl)Methyl]-N-[1-(2-Oxo-1,3-Oxathian-4-Ylidene)Ethyl]Formamide; Cycothiamin; Cycothiamine; N-((4-Amino-2-Methyl-5-Pyrimidinyl)Methyl)-N-(1-(2-Oxo-1,3-Oxathian-Formamid; Cyclothiamine; Cyclotiamine
- CAS编号6092-18-8
- MFCD编号:MFCD01726485
- FDA UNII编号:FT8753F8R9
- 分子式:C13H16N4O3S分子量:308.36
- 产品CID: 1590386
- 产品分类有机原料 → 有机杂环化合物 → 二嗪类
物理性质
MSDS等安全信息
合成工艺路线路线简述
海关参考信息
- 2901210000-乙烯
2901220000-丙烯
2905121000-正丙醇
2912110000-甲醛 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2005182036-A1
优先权日:2002-08-02
标题:Medicinal composition containing an HMG-CoA reductase inhibitor
发明人：KONDO TATSUHITO; TAKAGI IKUO; NAKAYAMA MASATO; TORIZUMI YASUHIRO
权利人:SANKYO CO
摘要:A pharmaceutical composition for promoting the synthesis of vascular endothelial nitrogen oxide and/or maintaining or elevating the concentration of vascular endothelial nitrogen oxide in the blood, or a pharmaceutical composition for improving blood lipids. The pharmaceutical composition contains an HMG-CoA reductase inhibitor; and gamma-oryzanol, and/or thiamines. For treatment, the components of the composition can be administered together, as a composition, or separately.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Sakatoku J, Kiriyama T, Okita J, Tajiri K. [Clinical effects of cycothiamine (Cometamin) on neurogenic bladder: cystometric study]. Hinyokika Kiyo. 1968 Oct;14(10):767-9. Japanese.
合成参考文献
摘要:Drugs in Japan, 6(316), 1982
📝 需求与反馈
尽可能描述清楚需求与问题信息
